BioRestorative Therapies Analyst Price Targets

Wall Street analyst price targets and consensus rating for BioRestorative Therapies (BRTX).

Price Target Range — 2 Quarters

Analyst Consensus — 2 Analysts

1Buy

1Hold

Consensus RatingBuy# Analysts2Avg. Consensus PT$360Upside to Avg. PT+16189.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 6, 2026	Maxim Group	Michael Okunewitch	Downgrade	Buy→Hold	—
Aug 14, 2024	Roth MKM	Jonathan Aschoff	PT Raise	Buy	$15→$18
Jun 12, 2024	Roth MKM	Jonathan Aschoff	Maintained	Buy	$15

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Maxim Group Downgrades BioRestorative Therapies to Hold

Maxim Group analyst Michael Okunewitch downgrades BioRestorative Therapies (NASDAQ:BRTX) from Buy to Hold.

Benzinga Newsdesk

PRO
Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

Roth MKM analyst Jonathan Aschoff maintains BioRestorative Therapies (NASDAQ:BRTX) with a Buy and raises the price target from $15 to $18.

Benzinga Newsdesk

PRO
Roth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target

Roth MKM analyst Jonathan Aschoff reiterates BioRestorative Therapies (NASDAQ:BRTX) with a Buy and maintains $15 price target.

Benzinga Newsdesk

PRO
Roth Capital Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $15

Roth Capital analyst Jonathan Aschoff initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $15.

Benzinga Newsdesk

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

Upgrades

Benzinga Insights

PRO
Maxim Group Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $6

Maxim Group analyst Michael Okunewitch initiates coverage on BioRestorative Therapies (NASDAQ:BRTX) with a Buy rating and announces Price Target of $6.

Benzinga Newsdesk

BioRestorative Therapies Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

BioRestorative Therapies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Maxim Group Downgrades BioRestorative Therapies to Hold

PRO
Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

PRO
Roth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target

PRO
Roth Capital Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $15

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

PRO
Maxim Group Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $6

People Also Watch

People Also Watch

BioRestorative Therapies Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

BioRestorative Therapies Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROMaxim Group Downgrades BioRestorative Therapies to Hold

PRORoth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

PRORoth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target

PRORoth Capital Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $15

Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022

PROMaxim Group Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $6

People Also Watch

People Also Watch

PRO
Maxim Group Downgrades BioRestorative Therapies to Hold

PRO
Roth MKM Maintains Buy on BioRestorative Therapies, Raises Price Target to $18

PRO
Roth MKM Reiterates Buy on BioRestorative Therapies, Maintains $15 Price Target

PRO
Roth Capital Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $15

PRO
Maxim Group Initiates Coverage On BioRestorative Therapies with Buy Rating, Announces Price Target of $6